Bibliographie

  1. Susman, Ed. NCCN: Menopause Definition Required: When Considering Adjuvant Aromatase-Inhibitor Therapy in Breast Cancer. Oncology Times. 27(8):54 - April 25, 2005, National Comprehensive Cancer Network (NCCN)

  2. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55.

  3. Arjun Menta et al. Inflammatory Breast Cancer What to Know About This Unique, Aggressive Breast. Surgical clinics of North America. August 2018;98 (4):787-800.

  4. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623-49.

  5. González A, Lluch A, Aba E, Albanell J, Antón A, Álvarez I, et al. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol. 2017;19(5):616-24.

  6. Prognostic significance of serum lactate dehydrogenase in patients with breast cancer: a meta-analysis, D Liu, D Wang, C Wu, L Zhang, QiMei, G Hu,et al. Cancer Manag Res. 2019;11:3611-3619.

  7. Funasaka C, Naito Y, Kusuhara S, Nakao T, Fukasawa Y, Mamishin K, et al. The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis. The Breast. 2021; 58:50-6.

  8. Franzoi MA, Saúde-Conde R, Ferreira SC, Eiger D, Awada A, de Azambuja E. Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. Breast. 2021; 57:86-94.

  9. Vela Ruiz JM, Ferrer-Ponce DI, Sotelo MJ, Bustamante –Coronado R, León-Nué N. Bilateral breast carcinoma in visceral crisis Revista de la Facultad de Medicina Humana. 2021;21.

  10. Benjamin Gigliotti, M.D. Dec 2022. Hypercalcemia of malignancy. Disponible sur : Hypercalcemia of Malignancy | Endocrine Society.(Consulté le 17 août 2024).

  11. ANAES. Septembre 1997. Lecture critique de l’hémogramme : valeurs seuils à reconnaître comme probablement pathologiques et principales variations non pathologiques. Disponible sur : Hemogram.pdf (has-sante.fr).(Consulté le 17 août 2024).

  12. Aoife M Ryan, Carla M Prado, Erin S Sullivan, Derek G Power, Louise E Daly, Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition. 2019;67-68:110539.

  13. Ruohan Yang, Guanyu Lu, Zheng Lv, Lin Jia* and Jiuwei Cui*. Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study. 10.3389/fonc.2022.1048781.